Multivariate Cox proportional hazard analyses of OS in the CLL4 trial
| Significant variables . | HR (95% CI) . | P . |
|---|---|---|
| Analysis I | ||
| Epigenetic subgroup | ||
| n-CLL | — | — |
| i-CLL | 0.77 (0.52-1.13) | ns |
| m-CLL | 0.46 (0.24-0.83) | .021 |
| IGHV status (IGHV-M vs -U) | 0.62 (0.40-0.90) | .014 |
| del(17p) (present vs absent) | 5.19 (3.19-8.45) | <.001 |
| Age | 1.06 (1.04-1.08) | <.001 |
| Stage (A vs B+C) | 1.44 (1.04-2.00) | .026 |
| Analysis II | ||
| Epigenetic subgroup | ||
| n-CLL | — | |
| i-CLL | 0.82 (0.56-1.20) | ns |
| m-CLL | 0.46 (0.24-0.87) | .018 |
| IGHV status (IGHV-M vs -U) | 0.60 (0.40-0.90) | .014 |
| del(17p) (present vs absent) | 5.01 (3.08-8.14) | <.001 |
| Age | 1.06 (1.04-1.07) | <.001 |
| Significant variables . | HR (95% CI) . | P . |
|---|---|---|
| Analysis I | ||
| Epigenetic subgroup | ||
| n-CLL | — | — |
| i-CLL | 0.77 (0.52-1.13) | ns |
| m-CLL | 0.46 (0.24-0.83) | .021 |
| IGHV status (IGHV-M vs -U) | 0.62 (0.40-0.90) | .014 |
| del(17p) (present vs absent) | 5.19 (3.19-8.45) | <.001 |
| Age | 1.06 (1.04-1.08) | <.001 |
| Stage (A vs B+C) | 1.44 (1.04-2.00) | .026 |
| Analysis II | ||
| Epigenetic subgroup | ||
| n-CLL | — | |
| i-CLL | 0.82 (0.56-1.20) | ns |
| m-CLL | 0.46 (0.24-0.87) | .018 |
| IGHV status (IGHV-M vs -U) | 0.60 (0.40-0.90) | .014 |
| del(17p) (present vs absent) | 5.01 (3.08-8.14) | <.001 |
| Age | 1.06 (1.04-1.07) | <.001 |
Two multivariable models were built (Analysis I and II) for the OS of UK CLL4 patients using a step-wise backward elimination process. The 2 models shown here include all significant predictors remaining at the end of the backward elimination analyses. Analysis I: Variables included at the start of the backward elimination process were epigenetic subgroups, age at randomization, sex, treatment, stage, IGHV mutational status, del(11q), and del(17p). The final model was based on 278 patients and 217 deaths. Analysis II: The variables included in the model initially were epigenetic subgroups, age at randomization, sex, treatment, stage, IGHV mutational status, del(11q), del(17p), TP53 mutation, combined NOTCH1 coding, and 3′UTR mutations and SF3B1 mutations. The final model was based on 278 patients and 217 events.
ns, nonsignificant.